# Orthofix Medical Inc.: overview

OFIX · Nasdaq · CIK 884624 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 23

Pages: [Overview](/companies/ofix.md) · [Financials](/companies/ofix/financials.md) · [Filings](/companies/ofix/filings.md) · [Insiders](/companies/ofix/insiders.md)

Latest reported revenue: [$210.9m](/filings/0001193125-26-333822.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-333822).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [197](/filings/0001193125-25-263670.md) | [216 d](/filings/0001193125-26-065189.md) | [194](/filings/0001193125-26-205003.md) | [203](/filings/0001193125-26-333822.md) | [206](/filings/0001193125-25-263670.md) | [220 d](/filings/0001193125-26-065189.md) | [197](/filings/0001193125-26-205003.md) | [211](/filings/0001193125-26-333822.md) |
| Gross margin | % | [68.7%](/filings/0001193125-25-263670.md) | [69.0% d](/filings/0001193125-26-065189.md) | [62.8%](/filings/0001193125-26-205003.md) | [68.7%](/filings/0001193125-26-333822.md) | [72.2%](/filings/0001193125-25-263670.md) | [71.1% d](/filings/0001193125-26-065189.md) | [70.9%](/filings/0001193125-26-205003.md) | [71.0%](/filings/0001193125-26-333822.md) |
| Operating margin | % | [(9.6%)](/filings/0001193125-25-263670.md) | [(5.3%) d](/filings/0001193125-26-065189.md) | [(25.2%)](/filings/0001193125-26-205003.md) | [(7.9%)](/filings/0001193125-26-333822.md) | [(8.3%)](/filings/0001193125-25-263670.md) | [0.2% d](/filings/0001193125-26-065189.md) | [(7.3%)](/filings/0001193125-26-205003.md) | [(3.9%)](/filings/0001193125-26-333822.md) |
| Net margin | % | [(13.9%)](/filings/0001193125-25-263670.md) | [(13.5%) d](/filings/0001193125-26-065189.md) | [(27.4%)](/filings/0001193125-26-333822.md) | [(6.9%)](/filings/0001193125-26-333822.md) | [(11.1%)](/filings/0001193125-25-263670.md) | [(1.0%) d](/filings/0001193125-26-065189.md) | [(10.6%)](/filings/0001193125-26-333822.md) | [(7.5%)](/filings/0001193125-26-333822.md) |
| Diluted EPS | $ per share | [(0.71)](/filings/0001193125-25-263670.md) | not reported | [(1.35)](/filings/0001193125-26-205003.md) | [(0.36)](/filings/0001193125-26-333822.md) | [(0.57)](/filings/0001193125-25-263670.md) | not reported | [(0.52)](/filings/0001193125-26-205003.md) | [(0.39)](/filings/0001193125-26-333822.md) |
| Free cash flow | $m | [6.3 d](/filings/0001193125-25-263670.md) | [14.1 d](/filings/0001193125-26-065189.md) | [(25.1)](/filings/0001193125-26-205003.md) | [4.5 d](/filings/0001193125-26-333822.md) | [2.5 d](/filings/0001193125-25-263670.md) | [16.8 d](/filings/0001193125-26-065189.md) | [(28.3)](/filings/0001193125-26-205003.md) | [(18.9) d](/filings/0001193125-26-333822.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [464](/filings/0000950170-24-025877.md) | [461](/filings/0000950170-25-026066.md) | [747](/filings/0001193125-26-065189.md) | [799](/filings/0001193125-26-065189.md) | [822](/filings/0001193125-26-065189.md) |
| Gross margin | % | [75.3%](/filings/0000950170-24-025877.md) | [73.2%](/filings/0000950170-25-026066.md) | [65.1%](/filings/0001193125-26-065189.md) | [68.3%](/filings/0001193125-26-065189.md) | [68.8%](/filings/0001193125-26-065189.md) |
| Operating margin | % | [(1.8%)](/filings/0000950170-24-025877.md) | [(2.9%)](/filings/0000950170-25-026066.md) | [(18.6%)](/filings/0001193125-26-065189.md) | [(10.6%)](/filings/0001193125-26-065189.md) | [(9.9%)](/filings/0001193125-26-065189.md) |
| Net margin | % | [(8.3%)](/filings/0000950170-24-025877.md) | [(4.3%)](/filings/0000950170-25-026066.md) | [(20.3%)](/filings/0001193125-26-065189.md) | [(15.8%)](/filings/0001193125-26-065189.md) | [(11.2%)](/filings/0001193125-26-065189.md) |
| Diluted EPS | $ per share | [(1.95)](/filings/0000950170-24-025877.md) | [(0.98)](/filings/0000950170-25-026066.md) | [(4.12)](/filings/0001193125-26-065189.md) | [(3.30)](/filings/0001193125-26-065189.md) | [(2.33)](/filings/0001193125-26-065189.md) |
| Free cash flow | $m | [0.7](/filings/0000950170-24-025877.md) | [(32.9)](/filings/0000950170-25-026066.md) | [(106)](/filings/0001193125-26-065189.md) | [(9.1)](/filings/0001193125-26-065189.md) | [(1.3)](/filings/0001193125-26-065189.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ofix/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Engine Capital Management, LP](/funds/1665590.md) | 2026-06-30 | $41.8m | 4,575,675 |  | Added +184,896 |
| [Juniper Investment Company, LLC](/funds/1794034.md) | 2026-06-30 | $40.6m | 4,442,543 |  | Added +465,584 |
| [Rubric Capital Management LP](/funds/1687509.md) | 2026-06-30 | $34.0m | 3,721,715 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $30.4m | 3,326,560 |  | Added +118,771 |
| [PARADIGM CAPITAL MANAGEMENT INC/NY](/funds/1037792.md) | 2026-06-30 | $30.2m | 3,300,499 |  | Reduced −4,400 |
| [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $29.8m | 3,264,000 |  | Added +564,000 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $15.8m | 1,731,108 |  | Added +75,659 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $9.6m | 1,048,081 |  | Added +109,196 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $8.7m | 953,148 |  | Added +45,716 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $8.1m | 887,282 |  | Added +698,158 |

## Recent filings

[All 1,284 filings](/companies/ofix/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-05 | 11:06 ET | [10-Q](/filings/0001193125-26-333822.md) | Quarterly report, period 2026-06-30 | 0001193125-26-333822 |
| 2026-08-05 | 11:03 ET | [8-K](/filings/0001193125-26-333817.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-333817 |
| 2026-07-02 | 20:00 ET | [8-K](/filings/0001193125-26-294445.md) | 7.01 Regulation FD disclosure | 0001193125-26-294445 |
| 2026-06-11 | 11:01 ET | [8-K](/filings/0001193125-26-266679.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-266679 |
| 2026-05-27 | 20:12 ET | [SCHEDULE 13D/A](/filings/0001214659-26-006790.md) | Ownership report, active investor, amended | 0001214659-26-006790 |
| 2026-05-21 | 12:00 ET | [8-K](/filings/0001193125-26-233429.md) | 7.01 Regulation FD disclosure | 0001193125-26-233429 |
| 2026-05-05 | 11:03 ET | [10-Q](/filings/0001193125-26-205003.md) | Quarterly report, period 2026-03-31 | 0001193125-26-205003 |
| 2026-05-05 | 11:02 ET | [8-K](/filings/0001193125-26-204999.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-204999 |
| 2026-04-29 | 20:20 ET | [DEF 14A](/filings/0001193125-26-191716.md) | Proxy statement, period 2026-04-29 | 0001193125-26-191716 |
| 2026-04-09 | 11:02 ET | [8-K](/filings/0001193125-26-148853.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-148853 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-065189.md), filed Feb 24, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/b523b990-9da7-4a31-92cd-f8b70498e83f)

## About the filer

- CIK: 884624
- Tickers: OFIX
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: not reported
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.